
An unfortunate day indeed as Replidyne (NASDAQ: RDYN) has terminated their licensing deal with Asubio Pharma for its lead drug candidate Faropenem and subsequently is expecting a charge of approximately $4.1M. Recall, Replidyne discontinued enrollment in a late-stage study testing its faropenem medoxomil oral antibiotic as a treatment for patients with acute chronic bronchitis due to an inability to secure a partner for the clinical program.
Concomitant to the terminated license agreement is termination of the supply agreement with Nippon Soda Co. Engineering costs and delayed compensation fees comprise a portion of the expected $4.1M charges.
The decision to end Faropenem is disappointing in a variety of dimensions and to a certain extent somewhat surprising that a partner could not be identified given how mature the asset is. The termination decision was executed in order to preserve cash and focus attention on the previously discussed strategic initiatives of the C. difficile infection program and novel anti-infective programs based on DNA replication inhibition technology. As of 31 May Replidyne had cash and short term investments totaling $71.5M.
*NOTE* Feel the power of the Colorado BioScience Association (HERE)!
*NOTE* Take a look at the new Boulder Biotech Company Tree (HERE)!
*NOTE* Read the new eBook CLSDF 2007 - What's In A Year? (HERE)!
If you enjoyed this post get free email or RSS updates (here).
Tuesday, June 24, 2008
Replidyne: Fare The Well Faropenem…
Posted by
Adam
at
7:24 AM
0
comments
Labels: CO Public: Replidyne
Monday, May 19, 2008
When It Rains It Pours - Replidyne Served

Replidyne (NASDAQ: RDYN) has been served with a Demand for Arbitration from MEDA Manufacturing alleging that the Company breached its obligations under a 2005 supply agreement. In April 2007, Replidyne provided notice to MEDA of its termination of the Supply Agreement in accordance with certain termination provisions, and believes that it did not have any obligations to MEDA under the Supply Agreement beyond May 2007.
The Demand seeks damages for breach of contract in the amount of approximately $2.3M plus interest and reimbursement of attorney fees and other costs incurred in proceedings. In addition, the Demand requests a judgment that Replidyne's termination of the Agreement was ineffective and that there is an obligation to continue to make annual minimum payment amounts of approximately $3.6M to MEDA remain in effect. If termination of the Agreement is determined to be ineffective Replidyne may also remain obligated additional future fees of up to approximately $2.6M (total approximating $$9.5M). Replidyne plans to vigorously defend itself against the allegations made in the Demand
*NOTE* Feel the power of the Colorado BioScience Association (HERE)!
*NOTE* Take a look at the new Boulder Biotech Company Tree (HERE)!
*NOTE* Read the new eBook CLSDF 2007 - What's In A Year? (HERE)!
If you enjoyed this post get free email or RSS updates (here).
Posted by
Adam
at
5:43 AM
0
comments
Labels: CO Public: Replidyne
Friday, May 09, 2008
Replidyne Provides 2008 Guidance

Yesterday Replidyne (NASDAQ: RDYN) held their annual shareholder meeting and 1Q08 conference call. With an anticipated burn rate of approximately $10M per quarter Replidyne’s current cash position just north of $78M positions operations to continue well into 2009. Considering the new strategic initiatives including restructuring, cash conservation and the difficult decision to terminate enrollment of the Phase III faropenem study management laid out the company plans to move forward with the C. difficile program with the goal of initiating a Phase I trial with REP 3123 as well as identifying an IND candidate from the DNA replication inhibition program. A spectrum of business development activity appears to be transpiring, though no details have been made public, some of which include: i) partnering talks are ongoing ii) looking at M&A opportunities, whereby the large cash position may make Replidyne more attractive to enable opportunistic actions and iii) a large international investment bank has been appointed to bring forth potential US and ROW opportunities, after all...the current market is frothy with deals. Needless to say with Replidyne’s seasoned and sophisticated management team it will not be surprising to see the share price and faropenem development pulled sharply out of their nose dives.
*NOTE* Feel the power of the Colorado BioScience Association (HERE)!
*NOTE* Take a look at the new Boulder Biotech Company Tree (HERE)!
*NOTE* Read the new eBook CLSDF 2007 - What's In A Year? (HERE)!
If you enjoyed this post get free email or RSS updates (here).
Posted by
Adam
at
7:28 AM
0
comments
Labels: CO Public: Replidyne
Wednesday, April 23, 2008
Replidyne Terminates Trial Enrollment to Preserve Cash

It is never a good feeling to wake up and hear that a pivotal late-stage clinical trial has terminated enrollment. However, there is a silver lining in such a difficult decision cloud…that is the sophisticated management at Replidyne (NASDAQ: RDYN) are savvy enough to examine the risk-reward profile for the continued burn of their remaining $78M cash position.
The Acute Exacerbation of Chronic Bronchitis study that has been halted is one in a package of four clinical trials, including two in community-acquired pneumonia and one in acute bacterial sinusitis, recommended as a way forward by the FDA for a new drug application submission for faropenem to treat these three adult community respiratory tract infections. Replidyne has not initiated the other three trials, and consistent with prior guidance, further faropenem development will depend on the securing a partner for the program.
Replidyne is required to conserve its cash position in order to maintain their array of research programs and to pursue strategic transactions. With cash in hand their remains an opportunity to advance the variety of additional pipeline assets such as the Clostridium difficile, DNA replication inhibition and pediatric faropenem programs. It is likely that there are meaningful value inflection points that may be achieved with these programs versus the obvious value previously demonstrated via the data from the previous nine Phase III and 3,000 patients enrolled in prior faropenem trials.
In fact, in my humble opinion, there appears to be so much value in Replidyne today that I am prepared to deviate a bit from my standard CLSDF protocol and make a prediction here…The oral community antibiotic market is very large and lucrative, with an average of 250 million prescriptions and sales of $7.5 billion per year over the last eight years. So rather than a seeking a partner deal, similar to what was disrupted with Forest Labs (NYSE: FRX), I predict a 2008 M&A transaction, and because of the program platform and the continued focus there that a big pharma deal north of $1B is in the works. Potential suitors may be GlaxoSmithKline (NYSE: GSK) via augmentin®, Pfizer (NYSE: PFE) via zithromax®, Ortho-McNeil via levaquin® or Abbott (NYSE: ABT) via omnicef®, just to name a few potential suitors. We shall see what happens…
*NOTE* Feel the power of the Colorado BioScience Association (HERE)!
*NOTE* Take a look at the new Boulder Biotech Company Tree (HERE)!
*NOTE* Read the new eBook CLSDF 2007 - What's In A Year? (HERE)!
If you enjoyed this post get free email or RSS updates (here).
Posted by
Adam
at
7:50 AM
0
comments
Labels: CO Public: Replidyne
Thursday, April 03, 2008
Replidyne: Reading Between the Retention Lines

It is no secret that Replidyne (NASDAQ: RDYN) is highly focused upon architecting and executing a new strategic alliance, to replace the Forest Labs (NYSE: FRX) deal that unwound, in order to shepherd the commercialization efforts of Faropenem.
A form 8K was filed with the SEC by the Louisville headquarters announcing a retention bonus has been put into effect with the Sr. VP of Corporate Development and the Chief Financial Officer. No need to name names and numbers here as that is easily identified by those who wish to seek out the info, no, what interests me more is the date of 30 September 2008 as the trigger date for the bonuses as well as the definitions of such an alliance whereby:
So I reckon that there are a couple of ways one can read between the lines of this retention program. At this moment I’ll elect the very bullish angle that a deal may be in the works and will be done by 3Q08, fingers crossed!
*NOTE* Feel the power of the Colorado BioScience Association (HERE)!
*NOTE* Take a look at the new Boulder Biotech Company Tree (HERE)!
*NOTE* Read the new eBook CLSDF 2007 - What's In A Year? (HERE)!
If you enjoyed this post get free email or RSS updates (here).
Posted by
Adam
at
7:11 AM
0
comments
Labels: CO Public: Replidyne
Thursday, February 28, 2008
Replidyne Announces Year-end Results

IMHO I remain incredibly optimistic about Replidyne’s (NASDAQ: RDYN), a leader in next-generation anti-infective products, direction (note: this in no why should be interpreted as investment advice). After being dealt a bum deal by the FDA re: a change in protocol for antibiotic trials, management at Replidyne has retrenched. With $90.3M in cash on the books as-of 31 December 2007 and a quarterly burn of approximately $18M it is full steam ahead with the Faropenem asset as Phase III enrollment continues for treatment of acute exacerbation of chronic bronchitis and preparation for three additional Phase III trials is likewise underway, one for treatment of acute bacterial sinusitis and two for treatment of community acquired pneumonia.
The search continues for a partner on the Faropenem asset and when and if one is identified and announced I would have to venture to guess that there will be a significant step up in value from today’s ~$53M market cap, which by the way indicates that the entity is trading below the sum of its parts.
Finally, great progress is being made in the pipeline with an expected IND filing this year for REP3123 in the Clostridium difficile program, and there is too an expectation for the identification of an IND candidate in the DNA replication inhibition program as an additional 2008 milestone.
***NOTE*** Take a look at the new Boulder Biotech Company Tree (HERE)!
***NOTE*** Read the new eBook CLSDF 2007 - What's In A Year? (HERE)!
If you enjoyed this post get free email or RSS updates (here).
Posted by
Adam
at
7:18 AM
0
comments
Labels: CO Public: Replidyne
Tuesday, January 29, 2008
Replidyne: New FDA Warning Letter
***1/30 POST UPDATE*** Here is a link to the letter from the FDA, click (here) to read.
There is not really too much to go on here, but …an FDA warning letter was recently issued relative to the antibiotic faropenem and the company filed an 8K with the SEC yesterday.
"On January 22, 2008, Replidyne, Inc. (the "Company") received a Warning Letter (the "Letter") from the U.S. Food and Drug Administration (the "FDA") pursuant to the completion of the FDA's review of clinical trials performed in connection with the December 2005 new drug application ("NDA") filed by the Company in support of faropenem medoxomil 300 mg tablets twice per day dose, in respect of which the FDA issued a non-approvable letter in October 2006. The clinical trials that supported this NDA were conducted by Bayer Corporation as a previous licensee of faropenem medoxomil. The Company intends to respond timely to the issues raised by the FDA."Faropenem, is a novel oral community antibiotic, which may be used as a first-line antibiotic. Faropenem is in late stage clinical development in adult patients with acute bacterial sinusitis, acute exacerbation of chronic bronchitis, and community-acquired pneumonia.
Interestingly when I went to look at how the Replidyne share price (NASDAQ: RDYN) was responding the thought was that the chart was going to look akin to a fall off a cliff however, at the open the stock is trading in the green. Hmmm…Can’t quite figure this one out? Does anyone have any thoughts on this letter or Redplidyne as a whole? Please leave a comment at the bottom of this post.
***Update*** It is the homestretch for the CLSDF Readers Company of the Year Award. ONLY TWO DAYS REMAIN TO CAST YOUR BALLOT! Voting ends on 31 January.
If you enjoyed this post get free email or RSS updates (here).
Posted by
Adam
at
7:54 AM
0
comments
Labels: CO Public: Replidyne
Tuesday, October 09, 2007
Replidyne: Is There Value in Antibiotics?
DISCLAIMER: This analysis in no way should be considered investment advice!
In an effort to keep the modeling skills a bit more than dull combined with a deep-rooted curiosity about the development or lack-there-of by big pharma of new anti-infectives I remain fascinated with the progression of Replidyne’s (NASDAQ: RDYN) portfolio, particularly the antibiotic Faropenem medoxomil.
FYI…For those who share my fascination there is an absolutely wonderful look at the entire antibiotic market by Ralph E. Christoffersen, Ph.D., Partner with Morgenthaler Ventures in last years Nature Biotechnology (Vol. 24 No.12) that you can read (here). Not to beat a dead horse but…people and publications of this caliber continue to validate the quality and sophistication of the Colorado bio-scape.
So…I set out to decide if the public markets are fairly valuing Replidyne. Here is the method to my madness: First I dove into attempting to size the potential markets for Faropenem, they include acute exacerbation of chronic bronchitis, bacterial sinusitis, community-acquired pneumonia and pediatric acute otitis media, and for REP8839 pediatric impetigo. Next I looked at the competitive landscape and for the most part decided that the market is highly competitive and thus assigned a relatively modest penetration rate to arrive at the targeted market available for capture. Then it was on to arriving at product pricing so I turned to what I believe to be the competitors such as Augmentin® by GlaxoSmithKline (NYSE: GSK), Omnicef® by Abbott (NYSE: ABT), Zithromax® by Pfizer (NYSE: PFE), Ketek® by Sanofi-Aventis (NYSE: SNY), Levaquin® by Ortho-Mcneil and, Altabax® by GlaxoSmithKline (NYSE: GSK). And considered the current average costs for dosing and duration to then derive a peak sales value.
As if the elements leading up to this next step were not difficult enough to arrive at I was then left to consider the variety of royalty streams. Some variables to consider are the original downstream license for Faropenem from Asubio Pharma and manufacturing relationship with Nippon Soda Supply as well as the upstream commercialization agreements with a to-be-named entity, formerly Forest Labs (NYSE: FRX), so I simply cut it in half and split the difference to yield a peak annual sales number. With this in hand I figured on an increase in sales of twenty percent per year over five years until peak annual sales are achieved. Based on this I then backed out manufacturing and operating costs, working capital and taxes, this left an estimate of free cash flow per indication.
Then an adjustment for risk was considered. I got a bit crazy here considering the safety and late stage data for Faropenem and that an NDA was filed despite the need to hold additional Phase III superiority studies, a generous discount was applied yet cranked it way down for the earlier stage REP8839 opportunities. This then left me with a free cash flow estimate that accounts for developmental risk. The final step is to then discount the free cash flow estimates via the incorporation of a traditional weighted average cost of capital (WACC) methodology. To derive the cost of equity I relied on Bloomberg for the beta and Bankrate.com for the risk-free rate, the market rate I more or less plucked this number out of the air though it seemed ‘reasonable’ to me, throw these elements all together and you have your capital asset pricing model. The final piece to calc’ing a WACC is determining the cost of debt; that was easy to do for as far as I can tell Replidyne is currently servicing no debt. Applying the WACC then left a discounted cash flow for each of the firm assets, sum them all up and there is the theoretical value of Replidyne.
Then I took this summed value and divided it by the number of shares outstanding and came up with a price of $7.01 compared with the trading value at the time of writing this post of $6.39. If my math and a whole lotta other stuff is correct then there is about a 10% price differential and would therefore propose that Replidyne is currently undervalued. But don’t take my word for it, the company recently had analyst coverage initiated by Morgan Stanley and Cowen & CO, and as of last month these folks are calling Replidyne either a buy or a strong buy and have noted a price target of $9.00. So that does lend some validation that my target price was ‘close’ and perhaps my model has some legitimacy but if you look at the delta from a percentage perspective there is a bit of a significant divide.
Anyway you slice it demand for new and more effective antibiotics continue to grow and here in Colorado we are rooting hard for Replidyne’s Faropenem and REP8839. The next earnings call is scheduled for 30 October 4:45pm EST, perhaps we may hear about a new partnership opportunity to replace the Forest Labs deal?
If you are interested in how I derived this value take a look at the model (here).
If you enjoyed this post, get free updates by email (here).
NOTE: Author holds a long position in RDYN.
Posted by
Adam
at
3:31 PM
0
comments
Labels: CO Public: Replidyne
Tuesday, September 25, 2007
REP3123 Coming After Vancocin®
Replidyne, Inc. (NASDAQ: RDYN) was featured in the 24 September issue of BioCentury, The Bernstein Report on BioBusiness! The article features some of the companies earlier stage pipeline, particularly REP3123 a MetRS inhibitor in preclinical development that may be more effective for severe Clostridium difficile-associated diarrhea (CDAD) than ViroPharma (NASDAQ: VPHM) and Eli Lilly’s (NYSE: LLY) Vancocin® or possibly Pfizer’s (NYSE: PFE) Flagyl® for moderate CDAD.
Replidyne believes the advantages of REP3123 may lay in the ability to reduce the C. difficile’s sporulation and toxin production and, via its narrow spectrum of activity have less effect on gut flora.
“Sporulation is a major problem with C. difficile,” said Chief Scientific Officer Nebojsa Janjic. “The spores are a dry-dust form of the bacteria that can persist in the gut and the environment for a long time. If you reduce spores in both places, you can reduce relapse rates.”
We should anticipate an announcement before years end on clinical trial strategy for 2008.
Posted by
Adam
at
9:00 AM
0
comments
Labels: CO Public: Replidyne
Monday, October 23, 2006
Replidyne: Silver Lining in FDA Letter

Following Replidyne’s (NASDAQ: RDYN) receipt of a non-approvable letter from the FDA for Faropenem® there are numerous reasons why there is a sliver lining in this non-approvable letter cloud.
First, and of paramount importance, the FDA had no SAFETY or Chemistry Manufacturing and Control issues. Second, the IP which covers composition of matter and methods of manufacturing are in place through 2015 with up to three additional years of protection through certain extensions. Third, a strong management team is backed by cash on hand of $134M (includes IPO proceeds) with a burn of approximately $30M however, certain additional capital needs for the required superiority and microbiological studies may be absorbed through a previous agreement with their partner Forest Labs (NYSE: FRX).
In short, a Post Action conference with FDA will be held. The news out of that meeting will provide insight as to the structures of the requisite studies to address the lack of placebo controlled data; recall that the studies were designed as non-inferiority (Faropenem® vs. current approved treatment). I would expect perhaps some additional information on 26 October, their scheduled earnings release date.
Posted by
Adam
at
2:26 PM
0
comments
Labels: CO Public: Replidyne
Friday, September 08, 2006
Something To Pay Attention To?

Merrill Lynch believes a decision should be reached by the FDA regarding Replidyne’s (NASDAQ: RDYN)Faropenem® approval for acute bacterial sinusitis by or before 20 October. One may be inclined to pay close attention to next Tuesday or Wednesday’s FDA panel review of rival Oscient Pharmaceutical (NASDAQ: OSCI) for Factive® also for the treatment of acute bacterial sinusitis and already approved for pneumonia and bronchitis.
In question next week will be the FDA’s updated guidance for the use of placebo controlled trials for new antibiotics such as Faropenem® and Factive®. If the FDA suggests the necessity of placebo controlled trials for either of the candidates it may negatively impact approval and launch timing. However, Merrill Lynch does not believe that such a trial will be necessary for Faropenem® based upon its safety profile. Replidyne may likely move in some directly or inversely correlated manner to OSCI as soon as the news of the panels decision is released.
Both Merrill Lynch and Cowen & CO. are now covering Replidyne. I have not determined what if any IB relationships may exist between the entities but certainly plan to answer that question.
Nearly 40 million Americans get sinusitis every year, according to the National Institutes of Health, and the U.S. market for treatments is estimated at nearly $6B.
Posted by
Adam
at
4:40 PM
0
comments
Labels: CO Public: Replidyne
Wednesday, June 28, 2006
Feather in Colorado's Cap

Happy to see that Replidyne, Inc. (Nasdaq: RDYN) began trading this morning at 11:00am! Next stop...approval for Orapem™!
Posted by
Adam
at
2:05 PM
1 comments
Labels: CO Public: Replidyne
Friday, June 23, 2006
Replidyne Off to See Wall Street
Replidyne, Inc. (Nasdaq: proposed RDYN) intends to offer up to Wall St. 5 million shares priced between $14 and $16 in next weeks highly anticipated IPO. What makes me exceedingly bullish on this offering is that unlike many biotech IPO’s that transpire in the midst of Phase II or III and sometimes even during Phase I clinical trials, Replidyne has filed an NDA with the FDA for its lead product Orapem™, the pipeline is robust, partnerships with bigphamra are strong and, the management team lead by Ken Collins has proven to be outstanding.
Posted by
Adam
at
2:55 PM
0
comments
Labels: CO Public: Replidyne
Thursday, April 06, 2006
The Best News I’ve Heard Today!
Great news for the Colorado bio-scape…
Replidyne Inc., a Louisville, Colorado based drug company focused on anti-infectives, has filed a registration statement with the SEC for a proposed initial public offering of its common stock. It plans to trade on the Nasdaq under ticker symbol RDYN, with Merrill Lynch and Morgan Stanley serving as lead underwriters. Replidyne has raised around $123 million in total VC funding since its 2000 inception, from firms like Morgenthaler, HealthCare Ventures, Perseus-Soros, Sequel Venture Partners, TPG Ventures and Duquesne Capital Management
Posted by
Adam
at
8:43 AM
0
comments
Labels: CO Public: Replidyne
Tuesday, February 14, 2006
Replidyne & Forest Labs Reach Agreement
Replidyne, Inc., and Forest Laboratories, Inc. (NYSE: FRX) announced that the two companies have entered into an agreement for the commercialization, development and distribution of Replidyne's new oral antibiotic, faropenem medoxomil, in the United States. Under the terms of the agreement, Forest will make a $50 million upfront payment to Replidyne as well as potential future milestone payments. In addition, Replidyne will receive royalty payments based on faropenem medoxomil sales. Forest and Replidyne will jointly oversee the development and regulatory approval of faropenem medoxomil and share all expenses for current and future development programs. Forest will be primarily responsible for sales and marketing of faropenem medoxomil. Replidyne also has an option to market and promote the product to pediatricians upon FDA approval of a pediatric formulation.
Posted by
Adam
at
11:08 AM
0
comments
Labels: CO Public: Replidyne
Wednesday, January 25, 2006
Replidyne Files NDA to FDA for Orapem™
Replidyne, Inc., a biopharmaceutical company focused on the discovery and development of new anti-infective drugs, kicked off 2006 with a bang and has submitted a New Drug Application to the FDA for Orapem™ for the treatment of acute bacterial sinusitis, community acquired pneumonia, acute exacerbations of chronic bronchitis and uncomplicated skin and skin structure infections.
This NDA is the first marketing approval submission for Orapem™ worldwide and it is also the first NDA submission for Replidyne. The Orapem™ submission is primarily based on data from eleven Phase III clinical trials which assessed the clinical and microbiological efficacy as well as the safety and tolerability profile in treating respiratory tract and skin infections. The safety database included more than 5,000 Orapem™ treated patients from clinical trials.
Congratulations to Replidyne for achieving such a significant milestone. We are incredibly excited about the potential FDA approval and subsequent commercialization focus.
Posted by
Adam
at
12:19 PM
0
comments
Labels: CO Public: Replidyne
Friday, September 09, 2005
Replidyne – NDA or Bust!
Replidyne continues their charge towards the planned 4Q05 NDA filing for Faropenem, an antibiotic for the treatment of respiratory tract infections. To aid these efforts the company has just closed on a $62.5 million Series D financing led by several new investors including: Duquesne Capital Management, Healthcare Investment Partners and MDS Life Sciences. Also participating in this financing round were existing investors HealthCare Ventures, TPG Ventures, Morgenthaler Ventures, Perseus-Soros BioPharmaceutical Fund, Sequel Venture Partners, Temasek Holdings and Quintiles Transnational.
This latest funding shall enable the anticipated Faropenem product launch in 2006 pending FDA final approval, in addition to enabling REP8839, an antibiotic for the treatment of antibiotic-resistant skin and staph infection causing bacteria, to be brought into clinical trials.
Might we see a 2006 IPO?
Posted by
Adam
at
10:25 PM
1 comments
Labels: CO Public: Replidyne
Thursday, July 07, 2005
Replidyne: Battling Bacterial Resistance
(The first look at a Colorado Series A (well really B) company)
Just a stones throw off of the Boulder Turnpike is where Replidyne resides. Under the leadership of Chief Executive Officer Ken Collins, Replidyne is focused upon discovering and developing novel anti-infective drugs to address a major, and growing, public health issue: bacterial resistance to existing antibiotics.
The management team most recently closed on a $40M Series B led by TPG Ventures, bringing the total capital raised to date to approximately $56M. The list of remaining investors for whom the velvet rope is held includes Health Care Ventures, Perseus-Soros Biopharmaceutical Fund, Morgenthaler, Sequel Partners, J&J Development Corp., and Temasek Holdings.
Replidyne is executing upon a diverse product portfolio. The most advanced channel of business includes Faropenem Daloxate (FD), a community antibiotic for adult respiratory tract infections. An NDA submission is scheduled for late 2005 with approval and launch expected in late 2006. Phase II studies on FD administered for a shorter course at higher dose and, preclinical work in pediatric applications add to the FD asset. Secondly, the company is in late-stage preclinical development of a novel tRNA synthetase inhibitor directed at resistant staphylococci aureus, and finally rounding out the pipeline is the technology with which the company was founded upon – novel mechanism-of-action compounds that inhibit bacterial DNA replication. A robust high-throughput screen strategy has yielded a number of promising molecules that have inhibited bacterial growth and activity in animal models of infection.
Nine Phase III FD studies demonstrated clinical and microbiological efficacy in addition to excellent safety and tolerability profiles. We are rooting for Replidyne to continue to replicate its formula for success.
Posted by
Adam
at
6:41 PM
1 comments
Labels: CO Public: Replidyne